Back to top
more

Roche Holding (RHHBY)

(Delayed Data from OTC)

$39.27 USD

39.27
2,641,410

-0.07 (-0.18%)

Updated Jul 19, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 28% (181 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Sheraz Mian headshot

Top Analyst Reports for Broadcom, Roche & Micron Technology

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Broadcom Inc. (AVGO), Roche Holding AG (RHHBY) and Micron Technology, Inc. (MU), as well a micro-cap stock Moving iMage Technologies, Inc. (MITQ).

Kinjel Shah headshot

Pharma Stock Roundup: JNJ, NVS Q2 Earnings, RHHBY's Positive Obesity Pill Data

by Kinjel Shah

J&J (JNJ) and Novartis (NVS) beat estimates for earnings and sales. Roche's (RHHBY) oral weight loss GLP-1 therapy achieves positive results in an early-stage study.

Sundeep Ganoria headshot

Novo Nordisk, Lilly Slide on Roche's Obesity Drug Study Data

by Sundeep Ganoria

Shares of obesity drugmakers Novo Nordisk (NVO) and Eli Lilly (LLY) lost market value on Wednesday after Roche (RHHBY) released positive early-stage data from a study on its obesity drug candidate.

Novartis (NVS) Tops on Q2 Earnings, Ups Operating Income View

by Zacks Equity Research

Novartis' (NVS) second-quarter earnings and sales beat estimates. Based on strong momentum, the company raises its operating income outlook for 2024.

Syros (SYRS) Stock Rises More Than 35% in 3 Months: Here's Why

by Zacks Equity Research

Syros (SYRS) is progressing well with the development of its pipeline candidate, tamibarotene, which is being studied for two different cancer indications.

Roche (RHHBY) Reports Positive Phase I Data on Obesity Drug

by Zacks Equity Research

Roche's (RHHBY) obesity candidate, CT-996, demonstrates clinically meaningful weight loss in the ongoing phase I study.

Roche Holding's (RHHBY) Accu-Chek SmartGuide Receives CE Mark

by Zacks Equity Research

Roche Holding (RHHBY) announces the receipt of CE Mark for its Accu-Chek SmartGuide CGM solution which is intended toward providing better diabetes management.

Here's Why Sarepta (SRPT) Stock Price Surged 57% YTD

by Zacks Equity Research

Sarepta (SRPT) surges on the commercial potential of its Elevidys, the first FDA-approved gene therapy for Duchenne muscular dystrophy.

The Zacks Analyst Blog Highlights Eli Lilly, Sanofi Merck, AstraZeneca's and Roche

by Zacks Equity Research

Eli Lilly, Sanofi Merck, AstraZeneca's and Roche are included in this Analyst Blog.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Nod to LLY's Kisunla, SNY's Dupixent Gets EU Nod for COPD

by Kinjel Shah

Eli Lilly (LLY) wins FDA approval for its Alzheimer's disease drug, Kisunla. (donanemab). Sanofi (SNY) and Regeneron's Dupixent gets approval for COPD in Europe.

Roche (RHHBY) Receives FDA Nod for Vabysmo Prefilled Syringe

by Zacks Equity Research

The FDA approves Roche's (RHHBY) Vabysmo prefilled syringe for treating three retinal conditions that can cause blindness.

Roche's (RHHBY) Combo Therapy Misses Lung Cancer Study Goals

by Zacks Equity Research

Roche (RHHBY) announces that its mid to late-stage lung cancer study evaluating the tiragolumab combination therapy compared with Keytruda fails to meet primary endpoints.

Roche (RHHBY) Gets Positive CHMP Recommendation for Its Drugs

by Zacks Equity Research

Roche (RHHBY) gets CHMP recommendation for a label expansion of ophthalmology drug Vabysmo (faricimab) and PiaSky (crovalimab) for the treatment of paroxysmal nocturnal haemoglobinuria.

Roche's (RHHBY) Ocrevus Subcutaneous Gets European Commission Nod

by Zacks Equity Research

Roche (RHHBY) obtains approval for the subcutaneous formulation of relapsing multiple sclerosis drug Ocrevus in Europe. In addition, a review of the company's MAA for gene therapy, Elevidys, is also underway.

FDA Expands Sarepta's (SRPT) DMD Gene Therapy Label

by Zacks Equity Research

Following the label expansion, Sarepta's (SRPT) Elevidys is approved to treat all DMD patients aged four years and older, regardless of ambulation status.

Roche (RHHBY), Ascidian Team Up for RNA Exon Editing Therapeutics

by Zacks Equity Research

Roche (RHHBY) gets exclusive, target-specific rights to Ascidian's RNA exon editing technology for undisclosed neurological targets for an initial payment of $42 million.

Regeneron (REGN) Outperforms Industry YTD: What Lies Ahead?

by Zacks Equity Research

Regeneron (REGN) maintains momentum on the back of Dupixent profits and efforts to develop oncology portfolio despite near-term challenges.

Roche (RHHBY) Reports Upbeat Data on Columvi From STARGLO Study

by Zacks Equity Research

Roche's (RHHBY) Columvi significantly extends survival in patients with relapsed or refractory diffuse large B-cell lymphoma in the phase III STARGLO study.

Roche (RHHBY) NSCLC Drug Alecensa Gets EC Nod for Label Expansion

by Zacks Equity Research

Roche's (RHHBY) Alecensa gets the European Commission's approval as the first and only targeted adjuvant treatment for people with ALK-positive early-stage lung cancer.

The Zacks Analyst Blog Highlights Roche, Wells Fargo, General Aerospace and Key Tronic

by Zacks Equity Research

Roche, Wells Fargo, General Aerospace and Key Tronic are part of the Zacks top Analyst Blog.

Sheraz Mian headshot

Top Analyst Reports for Roche, Wells Fargo & GE Aerospace

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Roche Holding AG (RHHBY), Wells Fargo & Company (WFC) and GE Aerospace (GE), as well as a micro-cap stock Key Tronic Corporation (KTCC).

Affimed (AFMD) Soars on Upbeat Follow-Up Data From NSCLC Study

by Zacks Equity Research

Affimed (AFMD) rallies 69% on positive follow-up efficacy data from its early to mid-stage study of the AFM24/Tecentriq combo therapy to treat heavily-pretreated EGFR wild-type NSCLC patients.

Novartis (NVS) Reports Positive Long-Term Data on CSU Drug

by Zacks Equity Research

Novartis (NVS) reports phase III data that confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria.

Kinjel Shah headshot

Pharma Stock Roundup: JNJ, MRK M&A Deals, SNY, RHHBY Drugs' Priority Review & More

by Kinjel Shah

J&J (JNJ) and Merck (MRK) announce the acquisitions of private biotechs. The FDA grants Priority Review tags to Sanofi's (SNY) and Roche's (RHHBY) regulatory applications.

Roche's (RHHBY) Inavolisib NDA Gets FDA Priority Review Tag

by Zacks Equity Research

The FDA grants priority review to Roche's (RHHBY) NDA for the inavolisib combination regimen for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation.